Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

Blerim Myftiu; Zylfije Hundozi; Faton Sermaxhaj; Afrim Blyta; Nexhmedin Shala; Fisnik Jashari; Hasime Qorraj Bytyqi; Ekrem Hyseni; Ilir Kurtishi

doi:10.12659/MSM.937856

31 August 2022 : Clinical Research

Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

Blerim Myftiu^12ABCDEFG*, Zylfije Hundozi^12ACDF, Faton Sermaxhaj^3ABD, Afrim Blyta^1ACDF, Nexhmedin Shala^12CD, Fisnik Jashari^12C, Hasime Qorraj Bytyqi^4CDF, Ekrem Hyseni^3BC, Ilir Kurtishi^3BC

DOI: 10.12659/MSM.937856

Med Sci Monit 2022; 28:e937856

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Chemotherapy protocols based on platinum- and taxane-based compounds.

Treatment regimen based on Platinum and/or Taxane	Number	Age (Mean±SD)
Neither platinum nor taxane	8	56.7±15.8
Platinum only and/or combination	60	60±10.1
Taxane only and/or combination	30	56.7±11.8
Platinum + Taxane and/or combination	22	62±10.3

SD – standard deviation.

Back to the Article

Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

Your Privacy